Walter G Bradley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2914877/publications.pdf Version: 2024-02-01



WAITED C. RDADLEY

#	Article	IF	CITATIONS
1	ALS risk factors: Industrial airborne chemical releases. Environmental Pollution, 2022, 295, 118658.	7.5	6
2	Airborne lead and polychlorinated biphenyls (PCBs) are associated with amyotrophic lateral sclerosis (ALS) risk in the U.S. Science of the Total Environment, 2022, 819, 153096.	8.0	9
3	Risk factors for amyotrophic lateral sclerosis: A regional United States caseâ€control study. Muscle and Nerve, 2021, 63, 52-59.	2.2	36
4	The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016–2018: The Ohio Population-Based ALS Registry. Neuroepidemiology, 2021, 55, 196-205.	2.3	5
5	Amyotrophic Lateral Sclerosis Risk, Family Income, and Fish Consumption Estimates of Mercury and Omega-3 PUFAs in the United States. International Journal of Environmental Research and Public Health, 2021, 18, 4528.	2.6	4
6	Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S. NeuroToxicology, 2021, 87, 128-135.	3.0	25
7	l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND. Journal of Neuropathology and Experimental Neurology, 2020, 79, 393-406.	1.7	42
8	Cyanobacterial neurotoxin BMAA and brain pathology in stranded dolphins. PLoS ONE, 2019, 14, e0213346.	2.5	37
9	Estimation of environmental exposure: interpolation, kernel density estimation or snapshotting. Annals of GIS, 2019, 25, 1-8.	3.1	23
10	Toenail mercury Levels are associated with amyotrophic lateral sclerosis risk. Muscle and Nerve, 2018, 58, 36-41.	2.2	24
11	Assessing Cyanobacterial Harmful Algal Blooms as Risk Factors for Amyotrophic Lateral Sclerosis. Neurotoxicity Research, 2018, 33, 199-212.	2.7	50
12	Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of I-Serine. Neurotoxicity Research, 2018, 33, 192-198.	2.7	24
13	Gene-Environment-Time Interactions in Neurodegenerative Diseases: Hypotheses and Research Approaches. Annals of Neurosciences, 2018, 25, 261-267.	1.7	31
14	Cytokine expression levels in ALS: A potential link between inflammation and BMAA-triggered protein misfolding. Cytokine and Growth Factor Reviews, 2017, 37, 81-88.	7.2	28
15	Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS). Journal of Neurology, 2017, 264, 1763-1767.	3.6	4
16	Phase I clinical trial of safety of L-serine for ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 107-111.	1.7	57
17	Detection of cyanobacterial neurotoxin β-N-methylamino-l-alanine within shellfish in the diet of an ALS patient in Florida. Toxicon, 2014, 90, 167-173.	1.6	59
18	ls exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 325-333.	1.7	72

#	Article	IF	CITATIONS
19	Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 7-20.	2.1	170
20	Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 118-123.	2.1	8